Biochemical studies have revealed that some normal cells express the Lex trisaccharide Galβ1→4(Fucα1→3)GlcNAc either on short-chain fucolipids or as a single immunodeterminant on glycolipid oligosaccharide side chains. Cancer cells, including those from colonic adenocarcinomas, express this antigen on longer type 2 blood group side chains as difucosylated or trifucosylated fucolipids. Moreover, sialylated forms of difucosylated Lex also accumulate in colon cancer but not in normal colonic mucosa. In the present study, six monoclonal antibodies which selectively recognize the various Lex-related antigens were used for immunohistochemical examination of these antigens in serial sections of human colonic tissue. All of these antigens were oncodevelopmental in human colon. Monoclonal antibodies anti-SSEA-1 and AH8-183, directed against short-chain, monofucosylated Lex, were unable to discriminate well between normal and malignant colonic tissue. However, the other four antibodies were much better at distinguishing cancer from normal tissue. FH6 was the most specific in that no normal tissues bound this antibody. However, FH6 failed to stain poorly differentiated cancers and some colloid-type carcinomas. FH4, which was also highly specific, stained almost all cancers, regardless of the degree of differentiation. FH4 primarily stained cancer cell cytoplasm, whereas the sialylated antigen defined by FH6 predominantly stained cell membranes. Differences were noted between the expression of Lex-related antigens in autopsied normal mucosa compared to mucosa of benign colonic diseases. Monoclonal antibodies recognizing long-chain polyfucosylated and sialylated Lex-related antigens in autopsied normal mucosa compared to mucosa of benign colonic diseases. Monoclonal antibodies recognizing long-chain polyfucosylated and sialylated Lex-related antigens appear to be useful tools for detection of colon cancer.

1

This work was supported by NIH grants GM23100, CA20026, and CA19224 (Y. F., S. H.); CP15738 from the Division of Cancer Cause and Prevention, National Cancer Institute, NIH (P. C. P., A. M. S., B. F. T.); the Veterans Administration Medical Research Service (S. H. I., M. Y., Y. S. K.); a Veterans Administration Medical Investigator Award (Y. S. K.); and a Veterans Administration Associate Investigator Award (S. H. I.).

This content is only available via PDF.